×
About 1,658 results

ALLMedicine™ Fallopian Tube Cancer Center

Research & Reviews  361 results

Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel i...
https://doi.org/10.1136/ijgc-2021-003316
International Journal of Gynecological Cancer : Official ... Girda E, Hou J et. al.

Jun 25th, 2022 - Preclinical evidence and early clinical trials have demonstrated the activity of SPL-108, a targeted agent that inhibits CD44 mediated induction of multidrug resistance specifically to paclitaxel and platinum agents. We conducted a phase I, open l...

Blood Collection From People With Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT02063464

Jun 24th, 2022 - Background: Using both in vitro and in vivo assays we have shown that human monocytes primed with Interferons alpha and gamma are tumoricidal and are capable of killing a number of tumor cell lines and human tumors implanted into immunocompromised...

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
https://clinicaltrials.gov/ct2/show/NCT04739800

Jun 23rd, 2022 - PRIMARY OBJECTIVE: I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by progression-free survival (PFS), as compared to phy...

D9319C00001- 1L OC Mono Global RCT
https://clinicaltrials.gov/ct2/show/NCT04884360

Jun 22nd, 2022 - This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or en...

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT02502266

Jun 22nd, 2022 - PRIMARY OBJECTIVES: I. To assess the efficacy and identify (in)active arm(s) of the combination of cediranib maleate (cediranib) and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by pr...

see more →

Guidelines  2 results

Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome.
https://doi.org/10.1097/AOG.0000000000002285
Obstetrics and Gynecology Reference;

Aug 24th, 2017 - Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family members with breast cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and managemen...

Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.
https://doi.org/10.1097/AOG.0000000000002296
Obstetrics and Gynecology;

Aug 24th, 2017 - Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family members with breast cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and managemen...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  225 results

Blood Collection From People With Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT02063464

Jun 24th, 2022 - Background: Using both in vitro and in vivo assays we have shown that human monocytes primed with Interferons alpha and gamma are tumoricidal and are capable of killing a number of tumor cell lines and human tumors implanted into immunocompromised...

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
https://clinicaltrials.gov/ct2/show/NCT04739800

Jun 23rd, 2022 - PRIMARY OBJECTIVE: I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by progression-free survival (PFS), as compared to phy...

D9319C00001- 1L OC Mono Global RCT
https://clinicaltrials.gov/ct2/show/NCT04884360

Jun 22nd, 2022 - This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or en...

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT02502266

Jun 22nd, 2022 - PRIMARY OBJECTIVES: I. To assess the efficacy and identify (in)active arm(s) of the combination of cediranib maleate (cediranib) and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by pr...

Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer
https://clinicaltrials.gov/ct2/show/NCT04991051

Jun 15th, 2022 - This cross-sectional, noninterventional, multicentre, epidemiological, observational study is designed to determine the prevalence of HRD in patients with newly diagnosed high-grade serous or endometrioid ovarian, primary peritoneal, and/or fallop...

see more →

News  73 results

Genomic Testing Challenges Persist
https://www.onclive.com/view/genomic-testing-challenges-persist

May 5th, 2022 - Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice. Structural changes in payment systems and decision-support too...

Olaparib Shows Comparable OS to Chemotherapy in BRCA+, Platinum-Sensitive, Relapsed Ovarian Cancer
https://www.onclive.com/view/olaparib-shows-comparable-os-to-chemotherapy-in-brca-platinum-sensitive-relapsed-ovarian-cancer

Mar 19th, 2022 - Single-agent olaparib (Lynparza) generated similar overall survival (OS) compared with non-platinum chemotherapy in heavily pretreated patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations, according to the final analysis o...

Adjuvant Olaparib Significantly Improves OS in BRCA+, High-Risk Early Breast Cancer
https://www.onclive.com/view/adjuvant-olaparib-significantly-improves-os-in-brca-high-risk-early-breast-cancer

Mar 17th, 2022 - At a median follow-up of 3.5 years, adjuvant olaparib (Lynparza) significantly improved overall survival (OS) vs placebo in patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who received prior chemotherapy before or...

SL-172154 Shows Favorable Tolerability in Platinum-Resistant Ovarian Cancer
https://www.onclive.com/view/sl-172154-shows-favorable-tolerability-in-platinum-resistant-ovarian-cancer

Nov 17th, 2021 - The investigative agent SL-172154 (SIRPα-Fc-CD40L) was found to be well tolerated, with no dose-limiting toxicities (DLTs) observed, in patients with platinum-resistant ovarian cancer, according to findings from a phase 1 dose-escalation trial pre...

Immunotherapy Could Still Have Pivotal Role in Ovarian Cancer
https://www.onclive.com/view/immunotherapy-could-still-have-pivotal-role-in-ovarian-cancer

Oct 6th, 2021 - Matthew Powell, MD Although enthusiasm remains for developing immunotherapies for patients with ovarian cancer, phase II studies evaluating the treatment’s efficacy in the recurrent population have been disappointing thus far, explained Matthew P...

see more →